Evorpacept is a Fusion Protein owned by ALX Oncology Holdings, and is involved in 12 clinical trials, of which 10 are ongoing, and 2 are planned.

evorpacept elicits anti-neoplastic activity by inhibiting CD47. CD47 is a molecule found on the surface of many cancers, acts as a don't eat me signal that protects the cancer from roving immune cells called macrophages. The drug candidate blocks this signal of CD47 and stimulates macrophages to eliminate tumor cells.

The revenue for Evorpacept is expected to reach a total of $6.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Evorpacept NPV Report.

Evorpacept was originated by Stanford University and is currently owned by ALX Oncology Holdings.

Evorpacept Overview

evorpacept is under development for the treatment of advanced solid tumors including colorectal cancer, indolent and aggressive B-cell non-Hodgkin lymphoma, gastro-esophageal junction cancers, acute myeloid leukemia, relapsed/refractory acute myeloid leukemia, epithelial ovarian, endometrial cancer, urothelial cancers, recurrent head and neck cancer squamous cell carcinoma and relapsed or refractory, higher risk myelodysplastic syndrome, non-Hodgkin lymphoma including mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, metastatic transitional (urothelial) tract cancer. It is administered intravenously. The drug candidate is a fusion protein containing high affinity CD47 binding domain of SIRPalpha linked to an inactive Fc region of human immunoglobulin.

It was also under development for breast cancer, leiomyosarcoma, non-small cell lung cancer, pancreatic, peritoneal, appendiceal, thymic cancers.

ALX Oncology Holdings Overview

ALX Oncology Holdings (ALXO) is an immune-oncology company that discovers and develops treatments for cancer and hematology indications. It is investigating its lead product candidate evorpacept (ALX148), a CD47 blocker for the treatment of hematologic and solid tumors; and ALTA-002, a SIRPa toll-like receptor agonist antibody conjugate (TRAAC) targeting advanced cancer. The company is also evaluating its lead candidate in combination with other agents against head and neck squamous cell carcinoma, gastric, urothelial, and breast cancer, myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin’s lymphoma. ALXO is headquartered in South San Francisco, California, the US.

The operating loss of the company was US$83.6 million in FY2021, compared to an operating loss of US$44.3 million in FY2020. The net loss of the company was US$83.5 million in FY2021, compared to a net loss of US$45.7 million in FY2020.

Quick View – Evorpacept

Report Segments
  • Innovator
Drug Name
  • Evorpacept
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.